Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akebia TherapeuticsFRA:AX9 -3.42%55 Cash Ratio is 0.94 as of Mar. 2026, which is 16% below its 10-year median of 1.12. GuruFocus rates FRA:AX9 with a GF Score™ of 55/100 and a GF Value™ of €1.12 (Fairly Valued). The stock has 5 warning signs investors should review. Among 974 Drug Manufacturers companies, Akebia Therapeutics ranks better than 60.16% on this metric.
Akebia Therapeutics has a Cash Ratio of 0.94. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Akebia Therapeutics's Cash Ratio or its related term are showing as below:
FRA:AX9'
s Cash Ratio Range Over the Past 10 Years
Min: 0.37 Med: 1.12 Max: 9.01
Current: 0.94
During the past 13 years, Akebia Therapeutics's highest Cash Ratio was 9.01. The lowest was 0.37. And the median was 1.12.
FRA:AX9's Cash Ratio is ranked better than 60.16% of 974
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs FRA:AX9: 0.94
Akebia Therapeutics (FRA:AX9) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Akebia Therapeutics Cash Ratio Related Terms
Akebia Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AX9 vs TKNO, ORGO, SIGA: Cash Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (FRA:AX9) has a Cash Ratio of 0.94 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Akebia Therapeutics and its competitors. This is 16% below median its historical median of 1.12. Over the past decade, Akebia Therapeutics' Cash Ratio has ranged from 0.37 to 9.01. According to the industry distribution chart, Akebia Therapeutics ranks #388 out of 974 companies in the Drug Manufacturers industry, placing it in the top 39.8%.
Is Akebia Therapeutics' Cash Ratio too high?
Akebia Therapeutics' current Cash Ratio of 0.94 is 16% below median its 10-year median of 1.12. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 9.01. The Drug Manufacturers industry median Cash Ratio is 0.61. Akebia Therapeutics' value of 0.94 is 54.1% above this industry median. Based on the distribution chart, Akebia Therapeutics ranks #388 out of 974 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akebia Therapeutics has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Cash Ratio compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #388 out of 974 companies for Cash Ratio. This puts Akebia Therapeutics in the upper half of its industry. The industry median Cash Ratio is 0.61. Akebia Therapeutics' value of 0.94 is 54.1% above this benchmark. Historically, Akebia Therapeutics' own Cash Ratio has ranged from 0.37 to 9.01 over the past decade. While the company's 10-year median is 1.12 vs. the industry median of 0.61, Akebia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 974 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akebia Therapeutics's current Cash Ratio of 0.94 is 54.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Akebia Therapeutics and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current Cash Ratio is 0.94, which is 16% below median its own 10-year median of 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (FRA:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.12, compared to a current price of €1.07 — trading 4.3% below its estimated fair value. The current Cash Ratio is 0.94, which is 16% below median its 10-year median of 1.12 and 54.1% above the Drug Manufacturers industry median of 0.61. Akebia Therapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Akebia Therapeutics (FRA:AX9), the current Cash Ratio is 0.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (FRA:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €1.07 is trading 4.3% below its estimated GF Value™ of €1.12.
GuruFocus considers Akebia Therapeutics to be Fairly Valued.
Key valuation signals for FRA:AX9:
Cash Ratio: 0.94 (16% below median its 10-year median of 1.12)
GF Value™: €1.12 vs. price of €1.07 (4.3% below fair value)
Industry Position: 54.1% above the Drug Manufacturers median (#388 of 974)
No single metric tells the full story. See the FRA:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
55GF Score
Get the complete analysis for FRA:AX9
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AX9 has been successfully added to your 
